Citation

BibTex format

@article{Singh:2025:10.1183/13993003.02231-2024,
author = {Singh, D and Guller, P and Reid, F and Doffman, S and Seppala, U and Psallidas, I and Moate, R and Smith, R and Kiraga, J and Jimenez, E and Brooks, D and Kelly, A and Nordenmark, LH and Sadiq, MW and Caballero, LM and Kell, C and Belvisi, MG and Pandya, H},
doi = {10.1183/13993003.02231-2024},
journal = {EUROPEAN RESPIRATORY JOURNAL},
title = {A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4},
url = {http://dx.doi.org/10.1183/13993003.02231-2024},
volume = {66},
year = {2025}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AU  - Singh,D
AU  - Guller,P
AU  - Reid,F
AU  - Doffman,S
AU  - Seppala,U
AU  - Psallidas,I
AU  - Moate,R
AU  - Smith,R
AU  - Kiraga,J
AU  - Jimenez,E
AU  - Brooks,D
AU  - Kelly,A
AU  - Nordenmark,LH
AU  - Sadiq,MW
AU  - Caballero,LM
AU  - Kell,C
AU  - Belvisi,MG
AU  - Pandya,H
DO  - 10.1183/13993003.02231-2024
PY  - 2025///
SN  - 0903-1936
TI  - A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4
T2  - EUROPEAN RESPIRATORY JOURNAL
UR  - http://dx.doi.org/10.1183/13993003.02231-2024
VL  - 66
ER  -
Download